Is C-PTSD an official diagnosis?

Yes in the ICD-11, where complex PTSD is coded as 6B41 and sits alongside PTSD as a sibling diagnosis. The DSM-5-TR, which is what most U.S. clinicians use, does not list C-PTSD as a separate diagnosis. Many U.S. trauma therapists still recognize and treat the construct, often using the ICD-11 framework. We do not diagnose C-PTSD at the clinic. Your therapist or psychiatrist is the right person to make that call.

Do the Feder ketamine trials apply to C-PTSD?

Honestly, not directly. The participants in the 2014 and 2021 Feder trials had chronic PTSD, with childhood and adult traumas represented, but the studies were not designed around the ICD-11 C-PTSD criteria. The findings are suggestive for people whose presentation overlaps with C-PTSD, but they are not proof. We tell candidates the same thing we are telling you here so expectations match the evidence.

Can ketamine make trauma worse?

Dissociative experiences during a ketamine infusion are common and expected. In trauma populations, those experiences can be destabilizing if there is no integration plan and no therapist. Pacing matters, screening matters, and a strong outside support system matters. We slow things down, screen carefully, and decline cases where the setup does not look safe. That is not a guarantee of outcome, but it is how we try to reduce risk.

Should I do ketamine without a trauma therapist?

We strongly prefer that you have an established trauma therapist before starting infusions, and we will say so directly during your consultation. Ketamine can open a window where trauma material becomes more accessible. Without a therapist to help you process what comes up between sessions, the work is harder and the risk of destabilization is higher. We can suggest local referrals if you do not have one yet.

How is the C-PTSD protocol different from the standard PTSD protocol?

Same molecule, different pacing. People whose presentation is more consistent with C-PTSD usually need a longer stabilization phase before infusions, more space between sessions, and more coordinated integration work with their therapist. We may also recommend starting at a lower dose and titrating up. The protocol is built around the person, not just the diagnosis label.

Ketamine for Complex PTSD: What the Evidence Does and Doesn't Say

PTSD vs. complex PTSD — the ICD-11 distinction

Complex PTSD (C-PTSD) is not a separate diagnosis in the DSM-5-TR, the manual most U.S. psychiatrists and psychologists use day to day. It is a separate diagnosis in the World Health Organization's ICD-11 (2018), which introduced complex PTSD under code 6B41 as a sibling diagnosis to PTSD. The ICD-11 framework requires the three core PTSD clusters—re-experiencing, avoidance, and a persistent sense of current threat—plus three additional disturbances in self-organization: affect dysregulation, negative self-concept, and disturbed relationships.

That difference in framing matters clinically. Many people whose trauma started in childhood, lasted years, and involved repeated relational harm—rather than a single bounded event—feel that the standard PTSD label does not fully describe their experience. The ICD-11 description of C-PTSD often does. We hear this from patients constantly. The shame, the difficulty trusting people, the chronic sense that something is wrong with who you are—those features go beyond the classic PTSD picture.

None of this is something we diagnose at the clinic. We are not your therapist, and we will not tell you whether what you have is PTSD, C-PTSD, or something else entirely. That is a conversation for the person doing your trauma work. What we can do is talk honestly about what the ketamine literature shows, where it stops, and how we think about treatment when the picture is more complex.

Why C-PTSD is harder to study

The reason ketamine research has not landed cleanly on C-PTSD is that most randomized trials predate the formal ICD-11 construct or were designed around DSM-defined PTSD. Participants with C-PTSD-like presentations were almost certainly enrolled in the major trials, but they were not identified separately, and outcomes were not analyzed by C-PTSD criteria.

There is also a recruitment problem. Phase-based trauma treatment—the framework recommended by the International Society for the Study of Trauma and Dissociation (ISSTD, 2011 guidelines) for complex trauma—moves through stabilization, processing, and integration over months or years. Pulling people in the middle of that work into a tightly controlled drug trial is hard, and exclusion criteria for active dissociation, comorbid substance use, or severe self-harm tend to remove a significant slice of the C-PTSD population.

So when we discuss the ketamine evidence below, hold this caveat in mind: the trials are about chronic PTSD. They are suggestive for the C-PTSD population. They are not proof. Research suggests benefit; it does not promise it.

What the chronic-PTSD ketamine literature shows

Ketamine is FDA-approved as an anesthetic. Its use for PTSD, complex PTSD, depression, anxiety, and chronic pain is off-label. With that disclosure on the table, the evidence base for ketamine in chronic PTSD is one of the more interesting stories in psychiatric research over the last decade.

The seminal study is Feder et al., 2014, published in JAMA Psychiatry. The team at Mount Sinai randomized 41 patients with chronic PTSD to a single intravenous dose of ketamine or midazolam (an active comparator that controls for the dissociative experience without the same glutamatergic effects). At 24 hours, the ketamine group showed a significant and rapid reduction in PTSD symptoms compared with midazolam. It was the first trial to suggest that a single ketamine infusion could move PTSD symptoms in hours rather than weeks.

The follow-up was Feder et al., 2021, published in the American Journal of Psychiatry. This was the first randomized controlled trial of repeated ketamine for chronic PTSD. Participants received six infusions over two weeks. At week two, the ketamine arm scored 11.88 points lower on the CAPS-5 (Clinician-Administered PTSD Scale) than the midazolam arm—a clinically meaningful difference. Effects were strongest for intrusion symptoms and negative alterations in cognition and mood. Several participants who responded maintained gains for weeks afterward, though durability varied considerably.

Subsequent work, including open-label studies and small randomized trials in veterans and first responders, has broadly supported these findings, while making clear that ketamine is not a standalone fix and that response rates fall well short of universal. We have written more about that body of evidence in our overview of ketamine for PTSD, and specifically in the cohort articles on veterans and first responders.

The Feder Mount Sinai trials in plain English

If you take one thing away from the Feder work, take this: the question those trials answered was not "does ketamine cure PTSD." It was "does ketamine, given on a short, structured schedule, reduce PTSD symptoms more than a credible placebo-like comparator?" The answer, in carefully selected participants with chronic PTSD, was yes—at least in the short term.

What the trials did not answer, and what we cannot answer for you in advance:

Whether the same effect holds in people whose presentation more closely matches ICD-11 complex PTSD.
How long the benefit lasts without ongoing therapy and, in some cases, maintenance infusions.
Who responds and who does not. The studies did not produce reliable predictors.
Whether ketamine alone, without trauma-focused therapy, produces lasting structural change versus a temporary lift.

That last point is where we land hardest. The mechanism people care about—ketamine as an NMDA receptor antagonist that boosts glutamate signaling and triggers a window of heightened neuroplasticity—suggests that the molecule opens a door. Walking through the door is therapy work. We have written about that mechanism in how ketamine works.

What ketamine doesn't replace: trauma-focused therapy

For complex trauma, the evidence-supported approach is phase-based: stabilization first (skills, regulation, safety), then processing (EMDR, prolonged exposure, cognitive processing therapy, internal family systems, somatic work, depending on the clinician and the fit), then integration. The ISSTD guidelines have anchored that framework for over a decade, and most experienced trauma therapists work some version of it.

Ketamine does not replace any of those phases. What it can do, when timed well, is widen the window where a person can tolerate processing work without flooding or shutting down. For some people that window is real and useful. For others it is too brief, too disorienting, or not enough on its own. We have learned to be careful about overselling.

Risk: dissociation in trauma populations

Dissociation during a ketamine infusion is normal and expected. The molecule is a dissociative anesthetic; that is part of how it works. For most patients, the experience is interesting, occasionally strange, and over within an hour. For people with significant trauma histories, particularly those with dissociative features already present in their day-to-day life, the experience can land differently.

The risks worth naming honestly:

Destabilization between sessions. Trauma material can surface in the days after an infusion. Without a therapist to help process it, that surfacing can feel like things are getting worse rather than better.
Re-traumatization during the infusion itself. Rare but real. We screen for this and pace accordingly.
Over-reliance on the medication. Ketamine is not a substitute for the slow work of stabilization and integration.

This is why we screen carefully and why we are not the right clinic for everyone. If you do not have a therapist, if you are in active crisis, or if you are looking for something to do instead of trauma therapy rather than alongside it, we will say so. Our overview of ketamine safety goes deeper into the medical side; the trauma-specific risks above are different and worth weighing on their own.

How we screen and integrate care in Nashville

For complex trauma, our intake conversation is longer than for a straightforward depression case. We want to understand your trauma history at a high level, your current therapy relationship, your medication list, your support system, and what you are hoping ketamine will do. We are looking for stability outside the clinic, not perfection.

If we move forward, the protocol is built around the person. Same molecule as our standard PTSD work, often slower pacing—more space between infusions, lower starting doses with titration, explicit coordination with your therapist between sessions. Marla Peterson, CRNA, oversees every infusion, with anesthesia-level monitoring throughout each session and the CRNA-led standard you would expect from a clinic where the lead clinician is the anesthesia provider, not a delegate. You can read more about what that role means in our piece on what a CRNA is.

We coordinate care actively. With your written consent, we share notes and timing with your therapist so the work between sessions stays connected to the work during them. Sessions at Music City Ketamine are $475 each, and we are transparent about cost from the first call. Insurance generally does not reimburse off-label ketamine for trauma work; we will tell you that up front rather than at checkout.

Honest expectations: research suggests ketamine can reduce PTSD symptoms meaningfully for a subset of patients with chronic PTSD. The C-PTSD-specific evidence is thinner. Some people respond strongly, some partially, and some not at all. We cannot predict in advance which group you will land in, and we will not pretend we can. What we can do is make the screening careful, the protocol thoughtful, the monitoring rigorous, and the conversation honest.